Drug Profile
Pegaspargase - Polaris Pharmaceuticals
Alternative Names: ASNase-PEG - Polaris Pharmaceuticals; PEG-asparaginase - Polaris PharmaceuticalsLatest Information Update: 25 Oct 2021
Price :
$50
*
At a glance
- Originator Polaris Pharmaceuticals
- Class Amidohydrolases; Antineoplastics; Polyethylene glycols
- Mechanism of Action Aspartate-ammonia ligase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 04 Jan 2017 Early research in Cancer in USA (Parenteral)